1. Atxn2-CAG100-KnockIn mouse spinal cord shows progressive TDP43 pathology associated with cholesterol biosynthesis suppression
- Author
-
Nesli-Ece Sen, Claudia Doering, Stéphane Dieterlé, R. Koenig, Suzana Gispert-Sanchez, Júlia Canet-Pons, Frédérique René, N. Hein-Fuchs, Anja Kerksiek, Melanie Vanessa Halbach, Aleksandar Arsovic, Gina Picchiarelli, D. Luetjohann, Jana Key, L.-E. Almaguer-Mederos, Raphaelle Cassel, Luc Dupuis, Georg Auburger, Goethe-Universität Frankfurt am Main, University Hospital Bonn, Mécanismes Centraux et Périphériques de la Neurodégénérescence, Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Paul-Ehrlich-Institute - Federal Institute for Vaccines and Biomedicines (EPI), and Dieterle, Stéphane
- Subjects
0301 basic medicine ,TIA1 ,[SDV]Life Sciences [q-bio] ,Tauopathy ,Olivo-ponto-cerebellar atrophy ,Demyelination ,Steroidogenesis ,Leukoencephalopathy ,Neuroanatomie ,Neuroinfammation ,Biology ,Neuroprotection ,lcsh:RC321-571 ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Stress granule ,Downregulation and upregulation ,Neuroinflammation ,medicine ,Animals ,Spinocerebellar Ataxias ,Gene Knock-In Techniques ,Amyotrophic lateral sclerosis ,lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry ,Ataxin-2 ,030304 developmental biology ,Denervation ,0303 health sciences ,medicine.disease ,Astrogliosis ,Cell biology ,[SDV] Life Sciences [q-bio] ,Disease Models, Animal ,Cholesterol ,030104 developmental biology ,Spinal Cord ,Neurology ,TDP-43 Proteinopathies ,Spinocerebellar ataxia ,030217 neurology & neurosurgery - Abstract
Large polyglutamine expansions in Ataxin-2 (ATXN2) cause multi-system nervous atrophy in Spinocerebellar Ataxia type 2 (SCA2). Intermediate size expansions carry a risk for selective motor neuron degeneration, known as Amyotrophic Lateral Sclerosis (ALS). Conversely, the depletion of ATXN2 prevents disease progression in ALS. Although ATXN2 interacts directly with RNA, and in ALS pathogenesis there is a crucial role of RNA toxicity, the affected functional pathways remain ill defined. Here, we examined an authentic SCA2 mouse model withAtxn2-CAG100-KnockIn for a first definition of molecular mechanisms in spinal cord pathology. Neurophysiology of lower limbs detected sensory neuropathy rather than motor denervation. Triple immunofluorescence demonstrated cytosolic ATXN2 aggregates sequestrating TDP43 and TIA1 from the nucleus. In immunoblots, this was accompanied by elevated CASP3, RIPK1 and PQBP1 abundance. RT-qPCR showed increase ofGrn,Tlr7andRnaset2mRNA versusEif5a2,Dcp2, Uhmk1andKif5adecrease. These SCA2 findings overlap well with known ALS features. Similar to other ataxias and dystonias, decreased mRNA levels forUnc80,Tacr1,Gnal,Ano3,Kcna2,Elovl5andCdr1contrasted withGpnmbincrease. Preterminal stage tissue showed strongly activated microglia containing ATXN2 aggregates, with parallel astrogliosis. Global transcriptome profiles from stages of incipient motor deficit versus preterminal age identified molecules with progressive downregulation, where a cluster of cholesterol biosynthesis enzymes includingDhcr24,Msmo1,Idi1andHmgcs1was prominent. Gas chromatography demonstrated a massive loss of crucial cholesterol precursor metabolites. Overall, the ATXN2 protein aggregation process affects diverse subcellular compartments, in particular stress granules, endoplasmic reticulum and receptor tyrosine kinase signaling. These findings identify new targets and potential biomarkers for neuroprotective therapies.
- Published
- 2021
- Full Text
- View/download PDF